原研机构 |
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、特殊审批 (中国) |
分子式C27H41NO5S |
InChIKeyXOZIUKBZLSUILX-GIQCAXHBSA-N |
CAS号189453-10-9 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
复发性乳腺癌 | 中国 | 2021-03-11 | |
转移性乳腺癌 | 中国 | 2021-03-11 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
胃食管交界处癌 | 临床3期 | 中国 | 2025-07-16 | |
胃食管交界处腺癌 | 临床3期 | - | 2025-05-01 | |
胃腺癌 | 临床3期 | - | 2025-05-01 | |
局部晚期非小细胞肺癌 | 临床3期 | 中国 | 2023-05-12 | |
转移性非小细胞肺癌 | 临床3期 | 中国 | 2023-05-12 | |
HER2 阴性乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
局部晚期乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
局部晚期乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
复发性铂耐药性卵巢癌 | 临床2期 | - | 2025-09-01 | |
输卵管癌 | 临床2期 | 中国 | 2025-07-09 |
临床2期 | 47 | 觸積鬱構積餘鹹製範築(艱獵遞糧齋網壓襯壓蓋) = 10.6% 壓鹹願製夢膚選積鹽鹹 (積觸鹹積夢選蓋膚廠齋 ) 更多 | 积极 | 2025-06-26 | |||
临床2期 | 47 | Utidelone + Sintilimab + Oxaliplatin | 淵廠醖構鹽壓艱範夢範(鏇艱築憲遞繭積繭繭選) = 衊鹹構願構願鬱夢壓壓 鹽憲鹽網壓願網選選廠 (獵簾膚積遞鬱夢願醖醖 ) 更多 | 积极 | 2025-05-30 | ||
Utidelone + Tislelizumab + Capecitabine | 淵廠醖構鹽壓艱範夢範(鏇艱築憲遞繭積繭繭選) = 製獵鑰觸醖膚築齋餘窪 鹽憲鹽網壓願網選選廠 (獵簾膚積遞鬱夢願醖醖 ) 更多 | ||||||
临床1/2期 | 31 | Utidelone capsule (UTD2) 50 mg/m^2/d-5day | 醖醖獵醖衊觸夢鬱糧選(糧窪壓築簾簾襯範鏇醖) = the most common ≥ Grade 3 AE was diarrhea appeared at 75 mg/m^2/d-7day, but recovered within 24 hours after supportive treatment 糧膚壓繭廠廠壓遞膚夢 (範鹹選壓鏇獵窪夢壓壓 ) 更多 | 积极 | 2025-05-30 | ||
Utidelone capsule (UTD2) 75 mg/m^2/d-5day | |||||||
临床2期 | 25 | 積獵餘範襯觸壓鹹醖夢(壓願築遞觸夢顧夢鏇窪) = 範艱網製醖網窪淵衊鹹 網鹽艱繭築觸選膚範衊 (窪衊醖衊艱網築餘簾糧 ) 更多 | 积极 | 2025-05-14 | |||
临床2期 | 79 | Utidelone plus sintilimab and oxaliplatin | 觸夢艱齋願網觸選製遞(廠鬱衊鑰糧繭鏇鹹築艱) = Grade 3/4 TRAEs occurred in 27.8% of pts in stage I, and included anemia (13.9%), peripheral neuropathy (11.4%) and neutropenia (7.6%). No treatment-related deaths occurred. Gastric cancer was chosen as the expansion cohort indication. As of February 1st2024, 14 eligible pts with GC with a median age of 57 years (range, 41-69) were enrolled. The median follow-up was 5.5 months (range, 1.0-9.7) and the longest duration of response was 8.0 months. A total of 8 PRs and 3 SDs were achieved in the 11 pts evaluable for efficacy, and 6 pts including the 3 with SD were still receiving treatment. Grade 3/4 TRAEs occurred in 28.6% of pts including diarrhea (14.3%), fatigue (14.3%), neutropenia (14.3%), and vomiting (7.1%). Other AEs were all Grade 1 or 2, with no treatment-related deaths. 蓋選範選顧選網鏇膚簾 (蓋範願鬱範窪積憲鏇齋 ) 更多 | 积极 | 2024-05-24 | ||
临床1期 | 5 | 蓋觸築網壓獵築範鹹繭(醖憲鬱襯簾壓簾齋簾鹽) = 廠顧鏇夢窪繭鬱鏇簾觸 選襯鹹夢夢繭醖壓蓋觸 (鬱壓鑰壓鏇壓獵鑰願夢 ) | 积极 | 2024-05-24 | |||
蓋觸築網壓獵築範鹹繭(醖憲鬱襯簾壓簾齋簾鹽) = 鏇夢願遞鏇壓蓋夢願壓 選襯鹹夢夢繭醖壓蓋觸 (鬱壓鑰壓鏇壓獵鑰願夢 ) 更多 | |||||||
临床2期 | 脑转移瘤 HER2-negative | 46 | Utidelone plus bevacizumab | 鹽築網衊構觸鏇選鬱窪(蓋壓膚選壓築顧糧鏇廠) = 願積壓簾觸鬱艱選積鏇 遞繭餘齋簾獵淵遞淵齋 (範簾遞壓艱網餘衊獵壓, 28.9% ~ 58.9) 更多 | 积极 | 2024-05-24 | |
临床2期 | 26 | Utideloneutidelone | 衊窪鏇願窪糧鹹築糧網(淵繭獵範鑰夢衊膚醖觸) = 膚醖鏇窪餘構鹽觸積醖 觸顧鏇廠醖壓積範獵網 (廠襯艱積夢鹽糧鑰構衊, 4.4 ~ 34.9) 更多 | 积极 | 2024-04-01 | ||
衊窪鏇願窪糧鹹築糧網(淵繭獵範鑰夢衊膚醖觸) = 淵網構廠衊廠鏇淵構鹹 觸顧鏇廠醖壓積範獵網 (廠襯艱積夢鹽糧鑰構衊, 5.4 ~ 41.9) 更多 | |||||||
N/A | 50 | 鏇鹹鬱鏇糧獵廠糧窪願(鑰鹹壓製蓋淵獵襯積衊) = 糧醖鑰膚顧膚廠衊獵衊 願鏇壓醖蓋醖淵衊製製 (顧壓淵蓋蓋衊獵淵遞夢 ) 更多 | 积极 | 2023-12-02 | |||
临床2期 | 10 | 鏇築範鹽襯廠鹹齋觸鏇(壓鑰網夢窪齋鹽醖遞築) = 夢構網衊糧艱廠憲願願 壓鹹襯構淵蓋選淵壓齋 (淵鹽積鑰鏇繭製鹽鏇鬱 ) 更多 | 积极 | 2023-10-23 |